Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
Under the agreement, Searchlight Pharma (“Searchlight”), Apotex's Specialty Pharma Division, will pursue marketing authorization for Qutenza® and market and distribute Qutenza® in Canada upon regulatory approval. Grünenthal will receive an upfront payment in addition to regulatory milestone payments and royalties.
Grünenthal acquired the global rights to Qutenza® in 2018 as part of its growth strategy. Since 2017, the company has invested more than €2 billion in successful M&A transactions and continues to generate additional value by integrating the acquired brands into Grünenthal's infrastructure, creating synergies throughout manufacturing, logistics, and commercial activities.
“We have continuously developed Qutenza® to expand its footprint and reach more patients in need – most notably through a relaunch and label extension in the US,” says Jan Adams, Chief Commercial Officer (CCO) at Grünenthal. “Apotex's exceptional commercial capabilities make them the ideal partner for us to tap into the Canadian market, one of the largest pharmaceutical markets in the world. We look forward to serving Canadian patients with this non-systemic, non-opioid treatment option and moving closer to our vision of a world free of pain.”
This agreement further reinforces Apotex's dedication to meeting the needs of patients with innovative solutions and expands Apotex's global portfolio of more than 550 pharmaceutical and consumer health products.
“Licensing the Canadian rights to Qutenza® enables us to improve the lives of Canadians by increasing the options for advanced pain management, specifically by bringing to Canada a differentiated and novel agent for the treatment of neuropathic pain that is already commercialized in the EU and US markets,” said Mark Nawacki, President of Searchlight. “This agreement demonstrates our continued momentum along our Journey of Health growth strategy and our dedication to enhancing patient care.”
Contacts
Florian DieckmannHead Global Corporate AffairsGrünenthal
Tel:+49 241 569-2555Florian.Dieckmann@grunenthal.comMedia contactApotex
media@apotex.comAbout Qutenza®
In Europe, Qutenza® is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit www.grunenthalhealth.com.
Qutenza® (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at www.qutenza.com.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the US Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group | Instagram: grunenthal
About Apotex and Searchlight Pharma
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Searchlight Pharma, the specialty pharma division of Apotex, executes best-in-class search, acquisition, and focused development of innovative and unique specialty healthcare products, with a core of its promoted products focused on women's health, dermatology, allergy, pain management and hospital specialty markets.
Learn more about us at www.apotex.com and at www.searchlightpharma.com.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Financial Year 2024: Weleda Achieves Record Turnover and Significantly Improves Profitability2.4.2025 11:30:00 CEST | Pressmeddelande
Turnover increased by 8.3% to EUR 456.2 million. Operating profit (EBIT excluding special effects) more than doubled from EUR 13.4 million to EUR 28.3 million. Both business units – Natural Cosmetics and Pharmaceuticals – delivered strong growth worldwide. Strategic growth drivers: internationalisation, digitalisation, innovation, and premiumisation. CEO Tina Müller: “2024 was a year of renewal for Weleda – and a very strong year for us economically. Our strategy of growth with responsibility is working.” CEO Tina Müller: “We have once again started the new financial year with strong momentum. We will continue our sustainable growth path with many innovations.”
Techem Sustainability Report 2024: Digitalization and innovation for more climate action1.4.2025 08:35:00 CEST | Pressmeddelande
Techem is expanding its digital platform to further increase sustainability and efficiency in buildings Expansion in residential and commercial properties: 1,514 new charging points for electric mobility in Germany Reduction of the company's own CO₂e emissions by around 18 percent compared to the base year 2020
CIVIS Media Prize 2025 | 29 productions nominated, 6 podcasts for public voting1.4.2025 08:19:49 CEST | Press Release
31.3.2025 Cologne (ots) | CIVIS Media Prize 2025 – 29 nominees for Europe's most important media prize for integration and cultural diversity have been shortlisted: Candidates for the CIVIS Media Prize include entries from ACB Stories, BR, cocktailfilms, Deutsche Welle, Deutschlandradio, Filmakademie Baden-Württemberg, kurhaus production Film & Medien, Little Dream Pictures, maximage, MDR, Neue Bioskop Film Leipzig, ORF, Pyramide Films, rbb, Salaud Morisset, SRF, Studio Zentral, SWR, Turbokultur, watson.ch, WDR and ZDF.
Xella achieves significant progress in CO₂ emissions reduction, circular economy, and occupational safety27.3.2025 11:53:22 CET | Press Release
Well positioned for sustainable growth with optimized network and enhanced processes
OpenCloud 2.0.0 offers enterprise services, support and “File Native Backup”27.3.2025 10:47:20 CET | Pressmeddelande
Berlin, Germany, March 27, 2025 – Following the successful release of OpenCloud 1.0 in February 2025, OpenCloud now launches its commercial offering including various enterprise service packages for its new solution for file management, file sharing and collaboration. OpenCloud 2.0.0 provides users with long-term software support, fast security updates, checks during update rollouts, high-availability solutions and personal support. OpenCloud can be run in in-house data centers or through selected partners. New feature for easy backup of large data volumes Version 2.0.0 also brings a new feature. “File Native Backup” makes it easy to back up data of any volume and includes a powerful full-text search. Unlike database-supported solutions, OpenCloud only requires a simple backup of the file system via a snapshot or file copy for a full, consistent backup. This means lower operating expenses, less risks of failure and process disruption, significant time saving, easier data backup and res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom